Siamak Moghadam-Kia, M.D., Rohit Aggarwal, M.D. and Chester V. Oddis, M.D.
Dr. Moghadam-Kia is Assistant Professor, Dr. Aggarwal is Associate Professor and Dr. Oddis is Professor, Myositis Center and Division of Rheumatology and Clinical Immunology, Department of Medicine, University of Pittsburgh School of Medicine, Pittsburgh, PA.
Within the past 12 months, Dr. Aggarwal has been a consultant to Bristol-Mers Squibb, Mallinckrodt and Octapharma, and done contracted research for Bristol-Mers Squibb, Genentech, Mallinckrodt and Pfizer; Drs. Moghadam-Kia and Oddis have no conflicts of interest relevant to this activity.
Albert Einstein College of Medicine, CCME staff, and interMDnet staff have nothing to disclose relevant to this activity.
Release Date: 12/04/2017
Upon completion of this Cyberounds®, you should be able to:
Discuss the role of systemic glucocorticoid therapy which is considered the mainstay of initial treatment of idiopathic inflammatory myopathies;
Describe the role of methotrexate or azathioprine, other immunosuppressive, immunomodulatory agents or biologic drugs that can be sequentially used alone or in various combinations in the management of polymyositis and dermatomyositis;
List the mechanism of action and common side effects of immunosuppressive or immunomodulatory therapies used in myositis treatment.
